Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs

ABSTRACT Today's gold standard in HIV therapy is combined antiretroviral therapy (cART). It requires strict adherence by patients and lifelong medication, which can lower the viral load below detection limits and prevent HIV-associated immunodeficiency but cannot cure patients. The bispecific T cell-engaging (BiTE) antibody technology has demonstrated long-term relapse-free outcomes in patients with relapsed and refractory acute lymphocytic leukemia. Here, we generated BiTE antibody constructs that target the HIV-1 envelope protein gp120 (HIV gp120) using either the scFv B12 or VRC01, the first two extracellular domains (1 + 2) of human CD4 alone or joined to the single chain variable fragment (scFv) of the antibody 17b fused to an anti-human CD3ε scFv. These engineered human BiTE antibody constructs showed engagement of T cells for redirected lysis of HIV gp120-transfected CHO cells. Furthermore, they substantially inhibited HIV-1 replication in peripheral blood mononuclear cells (PBMCs) as well as in macrophages cocultured with autologous CD8+ T cells, the most potent being the human CD4(1 + 2) BiTE [termed CD(1 + 2) h BiTE] antibody construct and the CD4(1 + 2)L17b BiTE antibody construct. The CD4(1 + 2) h BiTE antibody construct promoted HIV infection of human CD4−/CD8+ T cells. In contrast, the neutralizing B12 and the VRC01 BiTE antibody constructs, as well as the CD4(1 + 2)L17b BiTE antibody construct, did not. Thus, BiTE antibody constructs targeting HIV gp120 are very promising for constraining HIV and warrant further development as novel antiviral therapy with curative potential. IMPORTANCE HIV is a chronic infection well controlled with the current cART. However, we lack a cure for HIV, and the HIV pandemic goes on. Here, we showed in vitro and ex vivo that a BiTE antibody construct targeting HIV gp120 resulted in substantially reduced HIV replication. In addition, these BiTE antibody constructs display efficient killing of gp120-expressing cells and inhibited replication in ex vivo HIV-infected PBMCs or macrophages. We believe that BiTE antibody constructs recognizing HIV gp120 could be a very valuable strategy for a cure of HIV in combination with cART and compounds which reverse latency.

[1]  D. Dimitrov,et al.  One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells , 2017, Scientific Reports.

[2]  J. Kappes,et al.  Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein , 2017, Journal of Virology.

[3]  M. Farzan,et al.  Engineering antibody-like inhibitors to prevent and treat HIV-1 infection , 2017, Current opinion in HIV and AIDS.

[4]  A. Borkhardt,et al.  Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Dennis R Burton,et al.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.

[6]  D. Montefiori,et al.  Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. , 2015, The Journal of clinical investigation.

[7]  P. Moore,et al.  Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells , 2015, PLoS pathogens.

[8]  J. Mascola,et al.  Activation and lysis of human CD4 cells latently infected with HIV-1 , 2015, Nature Communications.

[9]  M. Nussenzweig,et al.  Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice , 2014, Cell.

[10]  M. Hudgens,et al.  Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART , 2014, PLoS pathogens.

[11]  B. Walker,et al.  Lessons to be Learned from Natural Control of HIV – Future Directions, Therapeutic, and Preventive Implications , 2013, Front. Immunol..

[12]  H. Einsele,et al.  Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.

[13]  P. Kufer,et al.  Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.

[14]  M. Friedrich,et al.  Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens , 2012, Molecular Cancer Therapeutics.

[15]  Andreas Wolf,et al.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.

[16]  R. Siliciano,et al.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.

[17]  Dongyang Yu,et al.  Spinoculation Triggers Dynamic Actin and Cofilin Activity That Facilitates HIV-1 Infection of Transformed and Resting CD4 T Cells , 2011, Journal of Virology.

[18]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Hsu,et al.  Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody , 2009, British Journal of Cancer.

[20]  R. Kischel,et al.  Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA , 2009, Journal of immunotherapy.

[21]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[22]  W. Marasco,et al.  T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120 , 2005, Gene Therapy.

[23]  R. Doms,et al.  Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins , 2003, Journal of Virology.

[24]  K. Salzwedel,et al.  Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120 , 2000, Journal of Virology.

[25]  C H Fox,et al.  Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. , 1999, AIDS.

[26]  M. L. Penn,et al.  A trans-receptor mechanism for infection of CD4-negative cells by human immunodeficiency virus type 1 , 1999, Current Biology.

[27]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[28]  S. Marsters,et al.  A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. , 1994, Journal of hematotherapy.

[29]  T. Hattori,et al.  Specific cytolysis of HIV-infected cells by lymphocytes armed with bifunctional antibodies. , 1992, Immunology letters.

[30]  A. Lanzavecchia,et al.  Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. , 1991, The EMBO journal.

[31]  K. Steimer,et al.  Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[33]  D. Ho,et al.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Tiffany Telarico,et al.  The role of endocytic recycling in autoimmunity. , 2012, Methods in molecular biology.